Frédéric Peyrade

11.6k total citations · 2 hit papers
138 papers, 5.7k citations indexed

About

Frédéric Peyrade is a scholar working on Oncology, Otorhinolaryngology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Frédéric Peyrade has authored 138 papers receiving a total of 5.7k indexed citations (citations by other indexed papers that have themselves been cited), including 61 papers in Oncology, 56 papers in Otorhinolaryngology and 53 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Frédéric Peyrade's work include Head and Neck Cancer Studies (56 papers), Lymphoma Diagnosis and Treatment (32 papers) and Chronic Lymphocytic Leukemia Research (23 papers). Frédéric Peyrade is often cited by papers focused on Head and Neck Cancer Studies (56 papers), Lymphoma Diagnosis and Treatment (32 papers) and Chronic Lymphocytic Leukemia Research (23 papers). Frédéric Peyrade collaborates with scholars based in France, Belgium and United States. Frédéric Peyrade's co-authors include Didier Cupissol, Ricard Mesı́a, Éva Remenár, Jan B. Vermorken, D. De Raucourt, József Erfán, Ihor Vynnychenko, Sylvie Rottey, Ricardo Hitt and Marco Benasso and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Frédéric Peyrade

130 papers receiving 5.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

2008 2.6k citations Ricard Mesı́a, Didier Cupissol et al. profile →
Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma

2017 449 citations Esma Saâda-Bouzid, Andy Karabajakian et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Frédéric Peyrade

Since Specialization

Citations

This map shows the geographic impact of Frédéric Peyrade's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frédéric Peyrade with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frédéric Peyrade more than expected).

Fields of papers citing papers by Frédéric Peyrade

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frédéric Peyrade. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frédéric Peyrade. The network helps show where Frédéric Peyrade may publish in the future.

Co-authorship network of co-authors of Frédéric Peyrade

This figure shows the co-authorship network connecting the top 25 collaborators of Frédéric Peyrade. A scholar is included among the top collaborators of Frédéric Peyrade based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frédéric Peyrade. Frédéric Peyrade is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study 2025 ·The Lancet Oncology ·Michael Wang, Wojciech Jurczak, Marek Trněný, David Belada, Tomasz Wróbel, Nilanjan Ghosh, Mary‐Margaret Keating, Tom van Meerten, (unknown), Gottfried von Keudell, Catherine Thiéblemont, Frédéric Peyrade, (unknown), Marc Hoffmann, Edith Szafer‐Glusman, Jennifer Lin, James P. Dean, Jutta K. Neuenburg, Constantine S. Tam	9
2	Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients 2024 ·Journal of Hematology & Oncology ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Frédéric Peyrade, (unknown), (unknown), (unknown), (unknown)	4
3	Long-Term Follow-up Study of Patients Aged 80 Years or Older Treated By Attenuated Chemotherapy Mini-CHOP Plus Anti-CD20 for DLBCL, Update of the LNH03-7B and LNH09-7B Lysa Trials 2024 ·Blood ·Jean‐Marie Michot, (unknown), Lucie Obéric, Fabrice Jardin, Vincent Delwail, (unknown), (unknown), Catherine Thiéblemont, Corinne Haïoun, Frédéric Peyrade, Hervé Tilly	0
4	Efficacy and safety of ibrutinib plus venetoclax in patients with mantle cell lymphoma (MCL) and TP53 mutations in the SYMPATICO study. 2024 ·Journal of Clinical Oncology ·Michael Wang, Wojciech Jurczak, Marek Trněný, David Belada, Tomasz Wróbel, Nilanjan Ghosh, Mary‐Margaret Keating, Tom van Meerten, Rubén Fernández-Álvarez, Gottfried von Keudell, Catherine Thiéblemont, Frédéric Peyrade, (unknown), Marc Hoffmann, Maoko Naganuma, Edith Szafer‐Glusman, Jennifer Lin, James P. Dean, Jutta K. Neuenburg, Constantine S. Tam	4
5	Efficacy and Safety of Ibrutinib Plus Venetoclax in Patients With Mantle Cell Lymphoma (MCL) and TP53 Mutations in the SYMPATICO Study 2024 ·Clinical Lymphoma Myeloma & Leukemia ·Wojciech Jurczak, Michael Wang, Marek Trněný, David Belada, Tomasz Wróbel, Nilanjan Ghosh, Mary‐Margaret Keating, Tom van Meerten, (unknown), Gottfried von Keudell, Catherine Thiéblemont, Frédéric Peyrade, (unknown), Marc Hoffmann, Maoko Naganuma, Edith Szafer‐Glusman, Jennifer Lin, James P. Dean, Jutta K. Neuenburg, Constantine S. Tam	0
6	Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results from the Randomized Phase 3 Sympatico Study 2023 ·Blood ·Michael Wang, Wojciech Jurczak, Marek Trněný, David Belada, Tomasz Wróbel, Nilanjan Ghosh, Mary‐Margaret Keating, Tom van Meerten, (unknown), Gottfried von Keudell, Catherine Thiéblemont, Frédéric Peyrade, Marc André, Marc Hoffmann, (unknown), Jennifer Lin, James P. Dean, Jutta K. Neuenburg, Constantine S. Tam	13
7	Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME 2021 ·Cancer Medicine ·(unknown), Amaury Daste, (unknown), Anderson Loundou, Florent Peyraud, (unknown), Christophe Le Tourneau, Frédéric Peyrade, Charlotte Dupuis, M. Alfonsi, Jérôme Fayette, (unknown), F. Huguet, Nicolas Fakhry, (unknown), Sébastien Salas	11
8	DPD status and fluoropyrimidines-based treatment: high activity matters too 2020 ·BMC Cancer ·Emmanuel Chamorey, Éric François, Marie‐Christine Etienne, Jean-Marc Ferrero, Frédéric Peyrade, Emmanuel Barranger, Alexandre Bozec, Rémy Largillier, (unknown), Julien Viotti, Renaud Schiappa, G. Milano	8
9	Impact of HPV-associated p16-expression and other clinical factors on therapeutic decision-making in patients with oropharyngeal cancer: A GETTEC multicentric study 2018 ·European Journal of Surgical Oncology ·Dorian Culié, R. Garrel, Julien Viotti, Renaud Schiappa, Emmanuel Chamorey, Nicolas Fakhry, Benjamin Lallemant, S. Vergèz, Agnès Dupret‐Bories, O. Dassonville, G. Poissonnet, J. Santini, Frédéric Peyrade, Karen Bénézery, Anne Sudaka, (unknown), F. Chapel, Bruno Guelfucci, Alexandre Bozec	8
10	Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma breakdown → 2017 ·Annals of Oncology ·Esma Saâda-Bouzid, (unknown), Andy Karabajakian, Virginia Palomar Coloma, Vincent Servois, Xavier Paolettí, Caroline Even, Jérôme Fayette, J. Guigay, Delphine Loirat, Frédéric Peyrade, Marie Alt, Jocelyn Gal, Christophe Le Tourneau	449
11	Place de la radiothérapie dans la prise en charge des lymphomes malins non hodgkiniens 2016 ·Cancer/Radiothérapie ·Lauris Gastaud, Benoît Rossignol, Frédéric Peyrade, Daniel Ré, Juliette Thariat, A. Thyss, J. Doyen	3
12	Pazopanib in patients with progressive recurrent or metastatic (R/M) salivary gland carcinoma (SGC): Further evaluation of efficacy including tumor growth rates (GR) analysis. H&N Unicancer Group PACSA trial with the REFCOR 2016 ·Annals of Oncology ·J. Guigay, François Bidault, Jérôme Fayette, Caroline Even, Didier Cupissol, Frédéric Rolland, Frédéric Peyrade, Brigitte Laguerre, Christophe Le Tourneau, Sylvie Zanetta, L. Bozec Le Moal, Christian Borel, Laurence Digue, (unknown), (unknown), Valérie Costes, A. Aupérin, Laurence Faivre	1
13	Induction chemotherapy-based larynx preservation program for locally advanced hypopharyngeal cancer: oncologic and functional outcomes and prognostic factors 2016 ·European Archives of Oto-Rhino-Laryngology ·Alexandre Bozec, Karen Bénézery, Marc Ettaiche, Emmanuel Chamorey, Clair Vandersteen, O. Dassonville, Gilles Poissonnet, (unknown), Jean‐Michel Hannoun‐Lévi, Marie-Eve Chand, (unknown), Esma Saâda, J. Guigay, Anne Sudaka, F Démard, J. Santini, Frédéric Peyrade	13
14	Z-BeEAM (Ibritumomab tiuxetan, Bendamustine, Etoposide, Cytarabine, Melphalan) before autologous stem cell transplantation is safe and efficient for refractory large B-cell lymphoma 2015 ·Experimental Hematology and Oncology ·Magalie P. Tardy, Lauris Gastaud, Mario Ojeda‐Uribe, (unknown), Salvatore Caruso, (unknown), (unknown), Antoine Thyss, Frédéric Peyrade	4
15	Treatment decisions for elderly patients with haematological malignancies: a dilemma 2012 ·The Lancet Oncology ·Frédéric Peyrade, Lauris Gastaud, Daniel Ré, Sandrine Pacquelet, Antoine Thyss	36
16	Management of radiation dermatitis in patients receiving cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: proposals for a revised grading system and consensus management guidelines 2011 ·Annals of Oncology ·J. Bernier, Elvio Russi, Bernhard Homey, Marco Merlano, Ricard Mesı́a, Frédéric Peyrade, Wilfried Budach	56
17	Acceptance of the 2009 A(H1N1) influenza vaccine among hospital workers in two French cancer centers 2010 ·Vaccine ·(unknown), D. Vanjak, Irène Kriegel, Jens Otto, Frédéric Peyrade, Marc Estève, Emmanuel Chamorey	51
18	Results of vocal rehabilitation using tracheoesophageal voice prosthesis after total laryngectomy and their predictive factors 2009 ·European Archives of Oto-Rhino-Laryngology ·Alexandre Bozec, Gilles Poissonnet, Emmanuel Chamorey, F Démard, J. Santini, Frédéric Peyrade, Cécile Ortholan, Karen Bénézery, Juliette Thariat, Anne Sudaka, (unknown), (unknown), (unknown), O. Dassonville	65
19	Docetaxel and gemcitabine combination in 133 advanced soft‐tissue sarcomas: A retrospective analysis 2006 ·International Journal of Cancer ·Jacques‐Olivier Bay, Isabelle Ray‐Coquard, Jérôme Fayette, Serge Leyvraz, Stéphane Cherix, Sophie Piperno‐Neumann, Christine Chevreau, Nicolás Isambert, Étienne Brain, (unknown), Axel Le Cesne, Angela Cioffi, Fabrice Kwiatkowski, Jean‐Michel Coindre, (unknown), Frédéric Peyrade, Jean‐Yves Blay, (unknown)	139
20	Septicémie à Edwardsellia tarda au cours d'une leucémie lymphoïde chronique 1997 ·La Revue de Médecine Interne ·Frédéric Peyrade, (unknown), B Taillan, (unknown), (unknown), P Dujardin	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact